Trial Profile
Novel Use Of Hydroxyurea in an African Region With Malaria
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Hydroxycarbamide (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms NOHARM
- 26 Nov 2017 Status changed from active, no longer recruiting to completed.
- 22 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2017.
- 25 Jun 2016 Status changed from recruiting to active, no longer recruiting.